Urinary Fractional Excretion of Phosphorus in Dogs with Spontaneous Chronic Kidney Disease
Veterinary Sciences, 2017 The increase of urinary fractional excretion of phosphorus (uFEP) may indicate phosphorus retention before the onset of hyperphosphatemia in the early stages of chronic kidney disease (CKD).
Cínthia Ribas Martorelli +6 more
doaj +1 more source
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword [PDF]
, 2017 The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) represents a selective update of the ...
Wheeler, DC, Winkelmayer, WC
core
Control of hyperphosphatemia beyond phosphate [PDF]
Kidney International, 2007 Hyperphosphatemia is a prevalent condition in the dialysis population and is associated with bad outcome. Block et al. present data from a post hoc analysis indicating that sevelamer, a noncalcium-containing phosphate binder, may confer a survival benefit in incident hyperphosphatemic hemodialysis patients.
openaire +2 more sources
Factors associated with delayed arteriovenous fistula maturation in chronic kidney disease patients [PDF]
, 2015 There has been an increasing trend of end stage renal disease patients requiring haemodialysis treatment worldwide. Vascular access remains the key component of haemodialysis treatment, unfortunately, the maintenance of this access remains a challenging ...
Huey Tean, Kok
core
Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter [PDF]
, 2018 Alteplase has been shown to be effective in preventing central venous access clotting in patients on hemodialysis. Because of a high phosphorus content in its excipient, it can inadvertently contaminate blood samples, leading the physician in care of the
Bardy, Daniel +3 more
core
Should cinacalcet be used in patients who are not on dialysis? [PDF]
, 2010 Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals with chronic kidney disease who are not receiving ...
Cannata, J.B. (Jorge), Fernández, Luis
core
Safety and Phosphate‐Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers
Clinical and Translational ScienceDespite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end‐stage kidney disease on dialysis.
Pablo E. Pergola +7 more
doaj +1 more source
Microbiota signatures in type-2 diabetic patients with chronic kidney disease - A Pilot Study [PDF]
, 2019 The human microbiota is paramount for normal host physiology. Altered host-microbiome interactions are part of the pathogenesis of numerous common ailments.
Chifiriuc, Mariana Carmen +9 more
core +1 more source
Saudi Medical Journal, 2015 Hyperphosphatemia is a major cause of morbidity and mortality in patients with chronic kidney disease. The association between hyperphosphatemia and increased risk of death from cardiovascular disease/vascular calcification has been well established for a long time.
openaire +2 more sources
Frontiers in NeurologyBackgroundPhosphate disorders, including hypophosphatemia and hyperphosphatemia, influence the prognosis of patients. We designed this study to explore the relationship between serum phosphate levels and mortality in traumatic brain injury (TBI) patients.
Ruoran Wang +3 more
doaj +1 more source